Piper Sandler on Apellis Pharmaceuticals (APLS): 'GA Doc Survey Suggests GA Market Growth In Doubt'
Tweet Send to a Friend
Piper Sandler analyst Biren Amin reiterated a Neutral rating and $32.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
